Ogata et al., 1997 - Google Patents
Absence of measles virus receptor (CD46) in lesions of subacute sclerosing panencephalitis brainsOgata et al., 1997
- Document ID
- 11173858622278589615
- Author
- Ogata A
- Czub S
- Ogata S
- Cosby S
- McQuaid S
- Budka H
- ter Meulen V
- Schneider-Schaulies J
- Publication year
- Publication venue
- Acta neuropathologica
External Links
Snippet
In this study we investigated pathological changes of the expression of the measles virus (MV) receptor, CD46, in subacute sclerosing panencephalitis (SSPE) brains. We analyzed CD46 expression in lesions of brain specimens from five SSPE patients in comparison to …
- 102100019144 CD46 0 title abstract description 94
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7371833B1 (en) | Nucleic acid molecules with specific recognition of native PrPSc, production and use | |
| JP2024012385A (en) | ALS-related diamino acid repeat-containing protein | |
| US9879257B2 (en) | Modulators of alpha-synuclein toxicity | |
| US8741868B2 (en) | Pharmaceutical composition including an HIF-2 alpha inhibitor as an active ingredient for preventing or treating arthritis | |
| JP2006526992A (en) | Methods for detecting cancer and monitoring cancer progression | |
| US20060160087A1 (en) | Monitoring and treatment of amyotrophic lateral sclerosis | |
| JP2012067109A (en) | MODULATOR OF α-SYNUCLEIN TOXICITY | |
| Ogata et al. | Absence of measles virus receptor (CD46) in lesions of subacute sclerosing panencephalitis brains | |
| Yang et al. | Kruppel-like factor 10 protects against acute viral myocarditis by negatively regulating cardiac MCP-1 expression | |
| JPH08509808A (en) | Neurofilament protein gene expression and detection of Alzheimer's disease | |
| US20020155513A1 (en) | Galectin expression is induced in cirrhotic liver and hepatocellular carcinoma | |
| SK15032001A3 (en) | A method for determining marker protein expression for diagnosing preclinical or clinical transmissible spongiform encephalopathies, a test kit and its use, and the use of antibody and oligonucleotides | |
| Itzhaki | Possible factors in the etiology of Alzheimer's disease | |
| JP2019158753A (en) | Biomarkers for lymphangioleiomyomatosis | |
| Ogata et al. | Expression of the interferon-α/β-inducible MxA protein in brain lesions of subacute sclerosing panencephalitis | |
| KR102443101B1 (en) | Biomarker composition for predicting the risk of developing neurodevelopmental disorders | |
| WO2023101599A2 (en) | A method of sorting a heterogenous macrophage population | |
| KR102077229B1 (en) | Composition for preventing or treating neurodegenerative disease comprising inducer or activator of nSMase2 | |
| Kong et al. | Neurotoxicity of cerebro-spinal fluid from patients with Parkinson’s disease on mesencephalic primary cultures as an in vitro model of dopaminergic neurons | |
| US20040157225A1 (en) | Diagnostic and therapeutic use of a nuclear restricted protein for alzheimer's disease and related neurodegenerative disorders | |
| KR102034929B1 (en) | Pharmaceutical composition for preventing or treating neurodegenerative diseases comprising NCKAP1 protein or gene thereof | |
| JP6721571B2 (en) | Use of 15 male reproductive proteins or combinations thereof | |
| KR102615797B1 (en) | Method for predicting the efficacy of treatment effects in glioblastoma by T cells | |
| KR101039996B1 (en) | Genes that control differentiation from hematopoietic stem cells to megakaryocytes and platelets and uses thereof | |
| Hosokawa et al. | Human oligodendroglial cells express low levels of C1 inhibitor and membrane cofactor protein mRNAs |